[{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor (AR)||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor (AR)||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor (AR)||NR3C4","graph1":"Oncology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Pedro Barata, MD, MSc","sponsor":"Essa Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor (AR)||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Pedro Barata, MD, MSc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pedro Barata, MD, MSc \/ Essa Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Pedro Barata, MD, MSc \/ Essa Pharma"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Caris Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Caris Life Sciences"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Masofaniten","moa":"NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Jefferies"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Jefferies"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"XenoTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ XenoTherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Essa Pharma \/ XenoTherapeutics"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"XenoTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Essa Pharma \/ XenoTherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ XenoTherapeutics"}]
Find Clinical Drug Pipeline Developments & Deals for Masofaniten
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
